Lv4
448 积分 2025-03-06 加入
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia
18小时前
已完结
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
18小时前
已完结
Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial
18小时前
已完结
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia
18小时前
已完结
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
18小时前
已完结
Erianin induces GSDMD-dependent pyroptosis and synergistically enhances doxorubicin efficacy via the PI3K/AKT signaling pathway in diffuse large B-cell lymphoma
21天前
已完结
Could treatment modification based on early response assessment improve results in DLBCL?
7个月前
已完结
Intratumoural vaccination via checkpoint degradation-coupled antigen presentation
7个月前
已完结
Adult Acute Lymphoblastic Leukemia: 2025 Update on Diagnosis, Therapy, and Monitoring
9个月前
已完结
The high-grade B-cell lymphomas: Double hit and more
11个月前
已完结
皖公网安备34019202002308
